- $288.68bn
- $313.21bn
- $54.07bn
US FDA extends review of AstraZeneca’s experimental breast cancer pill (updated)
UK Stocks-Factors to watch on May 27 (updated)
Brief: Astrazeneca Says US FDA Decision Date On Camizestrant Extended
US FDA extends review of AstraZeneca’s experimental breast cancer pill
Brief: Astrazeneca Reports Enhertu Recommended In EU For HER2+ Solid Tumours
Brief: AstraZeneca Says Datroway Approved In US For 1L Triple-Negative BC
Datroway approved in US for 1L triple-negative BC
Brief: EMA's CHMP Recommends Extension To Marketing Authorisation For Wegovy
EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug (updated)
EU regulator recommends positive opinion of AstraZeneca’s experimental breast cancer drug
Kelun, Merck's lung cancer combo improves survival in late-stage China trial (updated)
Kelun, Merck's lung cancer combo improves survival in late-stage China trial
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
China is investable again, for the nimble
RCS - General Assembly (GA - Business Leaders Primarily Use AI for Simple Tasks
China is investable again, for the nimble
Director/PDMR Shareholding
US Supreme Court rebuffs pharma challenge to Biden-era drug price
UK Stocks-Factors to watch on May 18 (updated)